再生医療の世界市場予測(~2027年)

◆英語タイトル:Regenerative Medicine Market Forecasts to 2028 – Global Analysis By Product (Progenitor and Stem Cell Therapies, Gene Therapies and Other Products), Material (Genetically Engineered Material, Synthetic material and Other Materials), Application (Oncology, Wound Care and Other Applications), End User and Geography

Stratistics MRCが発行した調査報告書(SMR23MR027)◆商品コード:SMR23MR027
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2023年2月
◆ページ数:約150
◆レポート形式:英語 / Eメール
◆納品方法:英語
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Global Site LicenseUSD4,150 ⇒換算¥630,800見積依頼/購入/質問フォーム
PDFUSD7,500 ⇒換算¥1,140,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)

❖ レポートの概要 ❖

ストラティスティックスMRC社は、世界の再生医療市場規模が2022年350.1億ドルから2028年739.4億ドルになり、予測期間中に年平均13.27%で成長すると予測しています。本報告書では、再生医療の世界市場を調査し、エグゼクティブサマリー、序論、市場動向分析、ファイブフォース分析、製品別(前駆細胞、幹細胞療法、遺伝子治療、その他)分析、材料別(遺伝子操作材料、合成材料、その他)分析、用途別(腫瘍、創傷ケア、その他)分析、エンドユーザー別(政府&学術研究機関、病院&診療所、商業)分析、地域別(北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ)分析、最近の動向、企業情報など、次のように掲載しています。また、企業情報としては、Smith & Nephew plc, Shenzhen SibionoGeneTech Co., Ltd., AstraZeneca, Aspect Biosystems, Integra LifeSciences Corporation, Novartis AG, Medtronic plc, Amgen, Inc., MiMedx Group, Baxterなどが含まれています。
・エグゼクティブサマリー
・序論
・市場動向分析
・ファイブフォース分析
・世界の再生医療市場規模:製品別
- 前駆細胞の市場規模
- 幹細胞療法の市場規模
- 幹細胞療法の市場規模
- その他製品の市場規模
・世界の再生医療市場規模:材料別
- 遺伝子操作材料の市場規模
- 合成材料の市場規模
- その他材料の市場規模
・世界の再生医療市場規模:用途別
- 腫瘍における市場規模
- 創傷ケアにおける市場規模
- その他用途における市場規模
・世界の再生医療市場規模:エンドユーザー別
- 政府&学術研究機関における市場規模
- 病院&診療所における市場規模
- 商業における市場規模
・世界の再生医療市場規模:地域別
- 北米の再生医療市場規模
- ヨーロッパの再生医療市場規模
- アジア太平洋の再生医療市場規模
- 南米の再生医療市場規模
- 中東・アフリカの再生医療市場規模
・最近の動向
・企業情報

According to Stratistics MRC, the Global Regenerative Medicine Market is accounted for $35.01 billion in 2022 and is expected to reach $73.94 billion by 2028 growing at a CAGR of 13.27% during the forecast period. Regenerative medicine repairs tissue or organs that have been damaged by disease, trauma, or congenital abnormalities, as opposed to the present clinical strategy, which focuses mostly on treating symptoms. The methods used to attain these breakthroughs include tissue engineering, cellular therapy, medical devices, and artificial organs. Regenerative medicine is an exciting field that aims to repair and restore the structure and function of damaged tissues and organs. It also intends to discover cures for permanently injured organs. This approach aims to find a cure for previously incurable illnesses and injuries.

According to the Alliance for Regenerative Medicine (ARM) 2021 report, the global financing in this market was raised to USD 22.7 billion in 2021 from USD 19.9 billion in 2020 to support 2,406 products that are under investigation.

Key players in the market

Some of the key players profiled in the Regenerative Medicine Market include Smith & Nephew plc, Shenzhen SibionoGeneTech Co., Ltd., AstraZeneca, Aspect Biosystems, Integra LifeSciences Corporation, Novartis AG, Medtronic plc, Amgen, Inc., MiMedx Group, Baxter, Eli Lilly & Co., Mesoblast Ltd., Bayer AG, Corestem, Inc., Bluebird Bio, Inc. and Regrow Biosciences Pvt. Ltd.

Key Developments:

In January 2021, Integra LifeSciences Holdings Corporation completed the acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies enabled Integra to provide more comprehensive complex wound management solutions to address patients.

In January 2021, Eli Lilly & Co. acquired Prevail Therapeutics with a deal to establish a gene therapy program at pharma giant anchored by Prevail’s Adeno-Associated Virus (AAV)9-based gene therapies for patients with neurodegenerative diseases. The deal broadened their commitment to address fatal genetic forms of neurodegenerative disease through new modalities. This acquisition bought critical technology and highly skilled teams to complement the existing expertise at Lilly.

In November 2020, Novartis collaborated with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of Acute Respiratory Distress Syndrome (ARDS). As a potential first ARDS therapy, remestemcel-L used Mesenchymal Stromal Cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Novartis intended to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of this license agreement.

In October 2020, Bayer acquired Asklepios BioPharmaceutical to broaden the innovation base in cell and gene therapy. This fueled Bayer’s cell and gene therapy platform with potential to bring treatments to patients across multiple disease areas with high unmet need.

In October 2018, Mesoblast Limited expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of new-borns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy (HIE).

Products Covered:
• Progenitor and Stem Cell Therapies
• Gene Therapies
• Tissue-Engineering
• Cell Therapies
• Other Products

Materials Covered:
• Genetically Engineered Material
• Synthetic material
• Biologically derived material
• Pharmaceutical

Applications Covered:
• Oncology
• Wound Care
• Cardiovascular
• Musculoskeletal
• Ophthalmology
• Other Applications

End Users Covered:
• Government & Academic Research Institutes
• Hospitals & Clinics
• Commercial Industries

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

❖ レポートの目次 ❖

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Regenerative Medicine Market, By Product
5.1 Introduction
5.2 Progenitor and Stem Cell Therapies
5.3 Gene Therapies
5.4 Tissue-Engineering
5.5 Cell Therapies
5.6 Other Products
6 Global Regenerative Medicine Market, By Material
6.1 Introduction
6.2 Genetically Engineered Material
6.2.1 Transgenics
6.2.2 Genetically Manipulated Cell
6.2.3 Gene-Activated Matrices
6.2.4 Neural Stem Cell
6.2.5 Three-Dimensional Polymer Technology
6.2.6 Fibroblast
6.3 Synthetic material
6.3.1 Artificial vascular graft material
6.3.2 Hydrogel material
6.3.3 Scaffold
6.4 Biologically derived material
6.4.1 Xenogeneic material
6.4.2 Collagen
6.5 Pharmaceutical
6.5.1 Biologic
7 Global Regenerative Medicine Market, By Application
7.1 Introduction
7.2 Oncology
7.3 Wound Care
7.4 Cardiovascular
7.5 Musculoskeletal
7.6 Ophthalmology
7.7 Other Applications
8 Global Regenerative Medicine Market, By End User
8.1 Introduction
8.2 Government & Academic Research Institutes
8.3 Hospitals & Clinics
8.4 Commercial Industries
9 Global Regenerative Medicine Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Smith & Nephew plc
11.2 Shenzhen SibionoGeneTech Co., Ltd.
11.3 AstraZeneca
11.4 Aspect Biosystems
11.5 Integra LifeSciences Corporation
11.6 Novartis AG
11.7 Medtronic plc
11.8 Amgen, Inc.
11.9 MiMedx Group
11.10 Baxter
11.11 Eli Lilly & Co.
11.12 Mesoblast Ltd.
11.13 Bayer AG
11.14 Corestem, Inc.
11.15 Bluebird Bio, Inc.
11.16 Regrow Biosciences Pvt. Ltd.
List of Tables
Table 1 Global Regenerative Medicine Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Regenerative Medicine Market Outlook, By Product (2020-2028) ($MN)
Table 3 Global Regenerative Medicine Market Outlook, By Progenitor and Stem Cell Therapies (2020-2028) ($MN)
Table 4 Global Regenerative Medicine Market Outlook, By Gene Therapies (2020-2028) ($MN)
Table 5 Global Regenerative Medicine Market Outlook, By Tissue-Engineering (2020-2028) ($MN)
Table 6 Global Regenerative Medicine Market Outlook, By Cell Therapies (2020-2028) ($MN)
Table 7 Global Regenerative Medicine Market Outlook, By Other Products (2020-2028) ($MN)
Table 8 Global Regenerative Medicine Market Outlook, By Material (2020-2028) ($MN)
Table 9 Global Regenerative Medicine Market Outlook, By Genetically Engineered Material (2020-2028) ($MN)
Table 10 Global Regenerative Medicine Market Outlook, By Transgenics (2020-2028) ($MN)
Table 11 Global Regenerative Medicine Market Outlook, By Genetically Manipulated Cell (2020-2028) ($MN)
Table 12 Global Regenerative Medicine Market Outlook, By Gene-Activated Matrices (2020-2028) ($MN)
Table 13 Global Regenerative Medicine Market Outlook, By Neural Stem Cell (2020-2028) ($MN)
Table 14 Global Regenerative Medicine Market Outlook, By Three-Dimensional Polymer Technology (2020-2028) ($MN)
Table 15 Global Regenerative Medicine Market Outlook, By Fibroblast (2020-2028) ($MN)
Table 16 Global Regenerative Medicine Market Outlook, By Synthetic material (2020-2028) ($MN)
Table 17 Global Regenerative Medicine Market Outlook, By Artificial vascular graft material (2020-2028) ($MN)
Table 18 Global Regenerative Medicine Market Outlook, By Hydrogel material (2020-2028) ($MN)
Table 19 Global Regenerative Medicine Market Outlook, By Scaffold (2020-2028) ($MN)
Table 20 Global Regenerative Medicine Market Outlook, By Biologically derived material (2020-2028) ($MN)
Table 21 Global Regenerative Medicine Market Outlook, By Xenogeneic material (2020-2028) ($MN)
Table 22 Global Regenerative Medicine Market Outlook, By Collagen (2020-2028) ($MN)
Table 23 Global Regenerative Medicine Market Outlook, By Pharmaceutical (2020-2028) ($MN)
Table 24 Global Regenerative Medicine Market Outlook, By Biologic (2020-2028) ($MN)
Table 25 Global Regenerative Medicine Market Outlook, By Application (2020-2028) ($MN)
Table 26 Global Regenerative Medicine Market Outlook, By Oncology (2020-2028) ($MN)
Table 27 Global Regenerative Medicine Market Outlook, By Wound Care (2020-2028) ($MN)
Table 28 Global Regenerative Medicine Market Outlook, By Cardiovascular (2020-2028) ($MN)
Table 29 Global Regenerative Medicine Market Outlook, By Musculoskeletal (2020-2028) ($MN)
Table 30 Global Regenerative Medicine Market Outlook, By Ophthalmology (2020-2028) ($MN)
Table 31 Global Regenerative Medicine Market Outlook, By Other Applications (2020-2028) ($MN)
Table 32 Global Regenerative Medicine Market Outlook, By End User (2020-2028) ($MN)
Table 33 Global Regenerative Medicine Market Outlook, By Government & Academic Research Institutes (2020-2028) ($MN)
Table 34 Global Regenerative Medicine Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 35 Global Regenerative Medicine Market Outlook, By Commercial Industries (2020-2028) ($MN)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 再生医療の世界市場予測(~2027年)(Regenerative Medicine Market Forecasts to 2028 – Global Analysis By Product (Progenitor and Stem Cell Therapies, Gene Therapies and Other Products), Material (Genetically Engineered Material, Synthetic material and Other Materials), Application (Oncology, Wound Care and Other Applications), End User and Geography)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆